Dublin, Oct. 05, 2017 (GLOBE NEWSWIRE) -- The "CAR-T r/r CLL Global Market Forecast" report has been added to Research and Markets' offering.
Novel immune-therapeutic approaches in development for CLL include monoclonal antibodies, bi-specific antibodies, anti-PD1/PDL-1 checkpoint inhibitors, and the CAR-T cell therapies including JCAR014/JCAR017 (Juno Therapeutics), KTE-C19 (Kite Pharma), and CTL019 (tisagenlecluecel-T)(Novartis Pharmaceuticals). These potential CAR-T therapies or their next generations e.g. armoured' CARs and humanized versions are in development. This product consists of a detailed Executive presentation (~130 slides, .pdf) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies in r/r CLL across 9 major Western markets to 2030.
A patient based flow methodology has been devised where possible intervention scenarios for CAR-T introduction are visualised so that the optimum product positioning can be assessed. In addition, an up-to-date review of CLL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T CLL competitive landscape. Pricing, cost effectiveness, manufacturing and logistical considerations are also discussed. All assumptions are clearly provided.
Key Topics Covered:
1. Executive summary 2. CAR-T treatment for r/r CLL - Commercial model: key outputs
- CAR-T eligible CLL patients/line of therapy 2017-2030 (Global)
- CAR-T eligible CLL patients/line of therapy to 2030 (US)
- CAR-T eligible CLL patients/line of therapy to 2030 (M5EU)
- CAR-T treated CLL patients/line of therapy to 2030 (Global)
- CAR-T treated CLL patients/line of therapy to 2030 (US)
- CAR-T treated CLL patients/line of therapy to 2030 (M5EU)
- CAR-T cell therapy: projected CLL revenue forecast per scenario ($000s) to 2030 (Global)
- CAR-T cell therapy: projected CLL revenue forecast per scenario ($000s) to 2030 (US)
- CAR-T cell therapy: projected CLL revenue forecast per scenario ($000s) to 2030 (M5EU)
3. Chronic lymphocytic leukaemia - Disease background
- Chronic lymphocytic leukaemia (CLL) - Disease background
- Chronic lymphocytic leukaemia (CLL) - Types of CLL
- Chronic lymphocytic leukaemia (CLL) - Risk factors
- Chronic lymphocytic leukaemia (CLL) - Symptoms
- Chronic lymphocytic leukaemia (CLL) - diagnosis and prognosis
- Chronic lymphocytic leukaemia (CLL) - Molecular genetics
- Chronic lymphocytic leukaemia (CLL) - Molecular genetics and prognostic significance
- Chronic lymphocytic leukaemia (CLL) - Common gene aberrations and prognostic significance
- Chronic lymphocytic leukaemia (CLL) - Disease staging
- Chronic lymphocytic leukaemia (CLL) - Prognostic Index
4. Chronic lymphocytic leukaemia - Epidemiology
- Chronic lymphocytic leukaemia (CLL) - Leukaemia incidence (US)
- Chronic lymphocytic leukaemia (CLL) - Incidence (US)
- Chronic lymphocytic leukaemia (CLL) - Incidence, age distribution and mortality (US)
- Chronic lymphocytic leukaemia (CLL) - Incidence, sex and race (US)
- Chronic lymphocytic leukaemia (CLL) - Leukaemia incidence (UK)
- Chronic lymphocytic leukaemia (CLL) - Incidence (UK)
- Chronic lymphocytic leukaemia (CLL) - Incidence, sex and age (UK)
- Chronic lymphocytic leukaemia (CLL) - Mortality and age (UK)
- Chronic lymphocytic leukaemia (CLL) - Incidence, mortality and country (UK)
- Chronic lymphocytic leukaemia (CLL) - Incidence and mortality in US, Canada, Europe, Australia, Japan
- Chronic lymphocytic leukaemia (CLL) - Prevalence in US, Canada, Europe, Australia, Japan
5. Chronic lymphocytic leukaemia - Treatment
- Chronic lymphocytic leukaemia (CLL) - Treatment requirements
- Chronic lymphocytic leukaemia (CLL) - Treatment agents
- Chronic lymphocytic leukaemia (CLL) - Treatment agents for relapsed/refractory CLL
- Chronic lymphocytic leukaemia - Treatment regimens by disease stage and risk category
- Chronic lymphocytic leukaemia - Treatment flow
- Chronic lymphocytic leukaemia - Transplantation
- Chronic lymphocytic leukaemia - Transplantation treatment scenarios
- Chronic lymphocytic leukaemia - Treatment challenges
6. Novel treatments for CLL - Immunotherapy approaches
- Chronic lymphocytic leukaemia - Immunotherapy approaches in development
- Chimeric Antigen Receptor T cells (CAR-T) - overview
- Chimeric Antigen Receptor T cells (CAR-T) - antigen selection
- CAR-T cell therapy: potential issues and challenges
- Steps in the manufacture of a CAR-T cell therapy
- CAR-T cell therapy for CLL- Key published studies
- CAR-T cell therapy for CLL- Key published studies - Studies in combination with ibrutinib
- CAR-T cell therapy for CLL- Summary of key published studies
- CAR-T cell therapy for CLL: pipeline analysis methodology
- CAR-T cell therapy for CLL: pipeline analysis - key findings
- Pipeline analysis table: Key ongoing CAR-T studies for CLL
- Key CAR-T cell programmes - Juno Therapeutics Inc. - Background
- Juno Therapeutics Inc. - Background: CAR and TCR R&D pipeline
- Juno Therapeutics Inc. - Background: CAR-T manufacturing process (JCAR017)
- Pipeline analysis: Key industry CAR-T studies for CLL - Juno Therapeutics
- Pipeline analysis: Key industry CAR-T studies for CLL - Novartis and CTL019 background
- Pipeline analysis: Key industry CAR-T studies for CLL - Novartis and CTL019 background: the path to commercialization
- Pipeline analysis: Key industry CAR-T studies for CLL - Novartis and CTL019 background: manufacturing process
- Pipeline analysis: Key industry CAR-T studies for CLL - Novartis and CTL019
- Pipeline analysis: Key industry CAR-T studies for CLL - Novartis and CTL119 - background
- Pipeline analysis: Key CAR-T studies for CLL - Novartis and CTL119
- Pipeline analysis: Key CAR-T studies for CLL - Kite Pharma/Gilead and CAR-T cell therapy background
- Kite Pharma/Gilead and CAR-T cell therapy - Axi-Cel (KTE-C19) manufacturing process
- Kite Pharma/Gilead: CAR-T R&D pipeline, September 2017
7. Novel treatments for CLL - Modelling commercial potential of CAR-T cell therapies
- CAR-T cell therapy for CLL: Target product profile
- CAR-T cell therapy for CLL: International Workshop on Chronic Lymphocytic Leukaemia (iwCLL) guidelines
- CLL modelling approach: patient flow/treatment scenarios
- Modelling approach: markets modelled in this analysis
- Pricing CAR-T cell therapy
- Pricing CAR-T therapies for indications other than paediatric ALL
- Price comparisons of existing therapies for first line and r/r CLL
- US cost burden projection for CLL with oral therapies as first line treatment
- Pricing comparisons with cell and novel immuno-oncology therapies
- Pipeline summary/potential launch sequence
- Model caveats and limitations
8. Bibliography
For more information about this report visit https://www.researchandmarkets.com/research/3...art_rr_cll
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs
